A novel nutraceutical formulation increases telomere length and activates telomerase activity in middle‑aged rats

Mol Med Rep. 2023 Dec;28(6):232. doi: 10.3892/mmr.2023.13119. Epub 2023 Nov 3.

Abstract

Telomeres are major contributors to cell fate and aging through their involvement in cell cycle arrest and senescence. The accelerated attrition of telomeres is associated with aging‑related diseases, and agents able to maintain telomere length (TL) through telomerase activation may serve as potential treatment strategies. The aim of the present study was to assess the potency of a novel telomerase activator on TL and telomerase activity in vivo. The administration of a nutraceutical formulation containing Centella asiatica extract, vitamin C, zinc and vitamin D3 in 18‑month‑old rats for a period of 3 months reduced the telomere shortening rate at the lower supplement dose and increased mean the TL at the higher dose, compared to pre‑treatment levels. TL was determined using the Q‑FISH method in peripheral blood mononuclear cells collected from the tail vein of the rats and cultured with RPMI‑1640 medium. In both cases, TLs were significantly longer compared to the untreated controls (P≤0.001). In addition, telomerase activity was increased in the peripheral blood mononuclear cells of both treatment groups. On the whole, the present study demonstrates that the nutraceutical formulation can maintain or even increase TL and telomerase activity in middle‑aged rats, indicating a potential role of this formula in the prevention and treatment of aging‑related diseases.

Keywords: Centella asiatica; dietary supplements; in vivo; telomerase activity; telomere length.

MeSH terms

  • Animals
  • Dietary Supplements
  • Leukocytes, Mononuclear / metabolism
  • Rats
  • Telomerase* / metabolism
  • Telomere / metabolism
  • Telomere Shortening

Substances

  • Telomerase

Grants and funding

The present study was supported by the European Union's ‘Horizon Europe’ framework programme project name: ‘MAgnetically steerable wireless Nanodevices for the tarGeted delivery of therapeutIc agents in any vascular rEgion of the body’ (ANGIE H2020-EIC-FETPROACT-2019). The study was also partially funded by the Spin-Off Company of the University of Crete, Toxplus S.A., by the start-up company LifePlus and by the Special Research Account of University of Crete (ELKE nos. 3464).